Jonathan Yen-Wen Yu Sells 804 Shares of Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu sold 804 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $82.64, for a total transaction of $66,442.56. Following the completion of the transaction, the chief operating officer directly owned 54,324 shares of the company’s stock, valued at approximately $4,489,335.36. The trade was a 1.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Jonathan Yen-Wen Yu also recently made the following trade(s):

• On Tuesday, July 7th, Jonathan Yen-Wen Yu sold 100 shares of Disc Medicine stock. The stock was sold at an average price of $82.50, for a total transaction of $8,250.00.
• On Friday, June 26th, Jonathan Yen-Wen Yu sold 300 shares of Disc Medicine stock. The stock was sold at an average price of $72.50, for a total transaction of $21,750.00.
• On Monday, June 22nd, Jonathan Yen-Wen Yu sold 9,700 shares of Disc Medicine stock. The stock was sold at an average price of $72.66, for a total transaction of $704,802.00.
• On Tuesday, June 16th, Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock. The shares were sold at an average price of $69.19, for a total transaction of $1,287,764.28.

Disc Medicine Stock Performance

NASDAQ:IRON opened at $78.84 on Friday. The company has a fifty day simple moving average of $74.60 and a two-hundred day simple moving average of $69.96. The company has a market cap of $302.35 million, a price-to-earnings ratio of -11.98 and a beta of 1.00. The company has a quick ratio of 24.14, a current ratio of 24.14 and a debt-to-equity ratio of 0.09. Disc Medicine, Inc. has a 52 week low of $40.00 and a 52 week high of $99.50.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.71) by $0.17. As a group, equities analysts anticipate that Disc Medicine, Inc. will post -6.61 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on IRON shares. Morgan Stanley upped their price target on Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Monday, June 15th. HC Wainwright boosted their price objective on Disc Medicine from $118.00 to $120.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Wedbush restated an “outperform” rating and set a $88.00 target price on shares of Disc Medicine in a research note on Wednesday, June 10th. Wall Street Zen raised shares of Disc Medicine from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a research note on Friday, July 17th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $106.00.

Institutional Trading of Disc Medicine

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. State of Wyoming purchased a new stake in Disc Medicine during the 2nd quarter worth about $25,000. ANTIPODES PARTNERS Ltd purchased a new position in shares of Disc Medicine in the 4th quarter valued at about $33,000. Allworth Financial LP purchased a new position in shares of Disc Medicine in the 2nd quarter valued at about $46,000. KBC Group NV acquired a new stake in shares of Disc Medicine during the 4th quarter worth about $80,000. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of Disc Medicine during the 4th quarter worth about $141,000. 83.70% of the stock is currently owned by institutional investors and hedge funds.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.